Biora Therapeutics, Inc. Cash Flow Conversion Efficiency
Biora Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Biora Therapeutics, Inc. (BIORQ) has a cash flow conversion efficiency ratio of 0.082x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.73 Million) by net assets ($-106.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biora Therapeutics, Inc. (2018–2023)
Cash flow conversion efficiency of Biora Therapeutics, Inc. from 2018 to 2023. This chart illustrates how Biora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biora Therapeutics, Inc. stock quote for real-time trading data and today's change.
Biora Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Biora Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biora Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see BIORQ company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
0.028x |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
-0.030x |
|
Ridgestone Mining Inc
V:RMI
|
0.012x |
|
Orion Equities Ltd
AU:OEQ
|
-0.017x |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
0.082x |
|
IG Design Group plc
LSE:IGR
|
0.380x |
|
Foresight Ventures VCT plc
LSE:FVEN
|
N/A |
|
Wingara AG Ltd
AU:WNR
|
-1.348x |
Annual Cash Flow Conversion Efficiency for Biora Therapeutics, Inc. (2018–2023)
The table below shows the annual cash flow conversion efficiency of Biora Therapeutics, Inc. from 2018 to 2023. Review Biora Therapeutics, Inc. (BIORQ) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-101.42 Million | $-48.50 Million | 0.478x | -24.07% |
| 2022-12-31 | $-102.29 Million | $-64.42 Million | 0.630x | -68.05% |
| 2021-12-31 | $-84.98 Million | $-167.49 Million | 1.971x | +27.23% |
| 2020-12-31 | $-106.99 Million | $-165.74 Million | 1.549x | +22.43% |
| 2019-12-31 | $-83.87 Million | $-106.12 Million | 1.265x | -28.18% |
| 2018-12-31 | $-36.97 Million | $-65.13 Million | 1.762x | -- |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more